Objectives: MRSA remains a major cause of severe nosocomial infections and the increased use of vancomycin and daptomycin for MRSA treatment over the last decade has led to the isolation of MRSA strains with decreased daptomycin susceptibility. In addition, a growing number of MSSA isolates with reduced susceptibility to daptomycin have been described lately. Surveillance of the emergence of such a daptomycin-non-susceptible MSSA population requires prompt and reliable daptomycin susceptibility testing. Therefore, this work aimed to evaluate the ability of commonly used methods to detect daptomycin resistance in clinical microbiological laboratories.
Introduction
Several European countries report a declining prevalence of infections with MRSA in hospitals. 1 However, MRSA remains an important nosocomial pathogen and its treatment represents a continuous challenge for clinicians, since several MRSA lineages have developed resistance to multiple antibiotic agents. 2 After several decades of routine use of vancomycin for the treatment of invasive MRSA infections, the incidence of infections with vancomycin-non-susceptible S. aureus has been rising steadily. Some of these isolates were previously demonstrated to be cross-resistant to daptomycin, which was originally considered an alternative therapy of last resort. 3 Daptomycin, a cyclic lipopeptide antibiotic active against Grampositive pathogens, including MRSA, was licensed by the US FDA in 2003. It was approved by the EMA for the treatment of complicated skin and skin structure infections, bacteraemia and rightsided infective endocarditis associated with Staphylococcus aureus in 2006/07. 4 Daptomycin has been increasingly used over the last decade leading to the occurrence of S. aureus isolates with decreased susceptibility in vitro and thus has infrequently been associated with treatment failure. 5 Reliable daptomycin susceptibility testing is a prerequisite to enable fast and accurate treatment decisions and to implement infection control practices.
Owing to time-and cost-effectiveness, laboratories usually use commercial systems for susceptibility testing. Manual systems mainly encompass gradient strip assays (Epsilometer tests), since disc diffusion has been shown to deliver unreliable results. 6 However, several studies reported inaccurate results for daptomycin susceptibility testing in comparison with broth microdilution (BMD). 7, 8 Inconsistent results were, amongst other reasons, attributed to the calcium-dependent activation of the anionic daptomycin molecule. 8 In this study, we evaluated the ability of three commercial gradient strip assays and the automated test system VITEK V R 2 to detect daptomycin resistance in comparison with BMD. The data assist microbiologists and clinicians in the interpretation of results obtained in daily clinical microbiology practice.
Materials and methods

Bacterial isolates
More than 25000 S. aureus isolates delivered to the National Reference Centre (NRC) for Staphylococci in Germany from 2008 to 2015 were cultured on sheep blood agar and confirmed as S. aureus by colony morphology and positive plasma coagulase reaction. They were tested for antibiotic susceptibility by BMD and further characterized by spa typing. 2 A total of 86 non-duplicate daptomycin-non-susceptible S. aureus isolates were selected according to the following criteria: (i) clonal background (as predicted by spa typing); (ii) isolation date; and (iii) geographical origin. These isolates were supplemented by 21 similar, daptomycin-susceptible isolates. The final selection comprised 107 isolates from 14 clonal linages among which were MSSA (oxacillin MIC 2 mg/L, n " 47) and MRSA (oxacillin MIC .2 mg/L, n " 60). All isolates with elevated daptomycin MICs in BMD (MIC .1 mg/L, range 2-8 mg/L) were defined as daptomycin-nonsusceptible according to EUCAST criteria. Table S1 (available as Supplementary data at JAC Online) contains detailed strain information.
Susceptibility testing
BMD testing for 19 different antibiotics (Table S1 ) was conducted according to EUCAST guidelines using a final inoculum of 5%10 5 cfu/mL and S. aureus ATCC 29213 as quality control. For daptomycin BMD, CAMHB (Becton Dickinson, Franklin Lakes, NJ, USA) was supplemented with calcium to achieve a physiological concentration of 50 mg/L. 8 The microdilution panels contained serial 2-fold dilutions of daptomycin (Standardized Daptomycin Powder, Cubist Pharmaceuticals, Lexington, KY, USA) ranging from 16 to 0.016 mg/L.
Daptomycin MIC gradient strips (Epsilometer tests) were obtained from three manufacturers: bioMérieux (Etest V R ; Marcy-l' Etoile, France), Thermo Scientific (M.I.C. Evaluator V R ; Waltham, MA, USA) and Liofilchem (Daptomycin MIC test strip V R ; Roseto degli Abruzzi TE, Italy). Epsilometer tests were performed on cation-adjusted Mueller-Hinton agar according to the manufacturer's instructions and using S. aureus ATCC 29213 as a control. For the purpose of comparative analysis with BMD MICs, MICs obtained by Epsilometer tests were rounded to the next higher log 2 dilution.
Automated susceptibility testing with the VITEK V R 2 system was performed using AST-P611 cards according to the manufacturer's recommendations.
Results and discussion
Epidemiological framework
The NRC for Staphylococci started routine daptomycin MIC determination in 2008. Ever since, we have received an increasing number of daptomycin-non-susceptible isolates. The increase contradicts a previous surveillance initiative that showed constant daptomycin-non-susceptibility rates over a period of 5 years in a worldwide strain collection. 9 This is most probably due to our function as a reference laboratory leading to an inherent bias towards drug-resistant strains. However, since 2012 the rise in MSSA isolates exhibiting increased daptomycin MICs is striking ( Figure S1 ). Daptomycin-non-susceptibility in MSSA has recently been reported in patients not previously exposed to daptomycin or glycopeptides, thus suggesting that de novo non-susceptibility might develop in the community. 10 To preserve daptomycin as an effective treatment option, it is essential that clinical microbiologists are aware of this non-susceptibility phenotype. This study was initiated to: (i) compare results from different commercial daptomycin susceptibility tests with special attention to the detection of daptomycinnon-susceptible MSSA; and (ii) to assist clinical laboratories in the interpretation of the results.
Daptomycin susceptibility test concordance
Based on a diverse strain collection we were able to demonstrate a high concordance between different susceptibility tests and BMD as a reference.
Essential agreement
MICs obtained by manual and automated test systems were generally in agreement with those obtained by BMD ( Figure 1 and Table 1 ). Only five isolate-MIC combinations displayed an MIC difference within a 4-fold dilution as compared with the reference method ( Figure 1 and Table 1 
Categorical agreement
Three isolate-MIC combinations resulted in false-resistant classification [major errors (MEs); M.I.C. Evaluator V R , Etest V R and VITEK V R 2, one isolate each (0.9%); Figure 1 ], whereas two isolate-MIC combinations were interpreted as false-susceptible [very major errors (VMEs); Daptomycin MIC test strip V R and VITEK V R 2, one isolate each (0.9%); Figure 1 ]. Thus, a categorical agreement between commercial gradient strip assays and reference BMD of 99.1% and 98.2% for the automated VITEK V R 2 system was achieved. MEs occurred in three different tests for a single isolate (Table S1 ), indicating that the MIC of this isolate (1.0 mg/L by BMD) might have been very close to the EUCAST breakpoint and highlighting the fact that no intermediate resistance category is defined for daptomycin. The fact, that we tested only a limited number of susceptible isolates and only two with an MIC of 1.0 mg/L might have led to an underestimation of MEs in this study.
Although nearly all MICs obtained by commercial daptomycin susceptibility tests showed essential agreement with BMD, MICs determined by VITEK V R 2, M.I.C. Evaluator V R and Daptomycin MIC test strip V R tended to be slightly higher (thus they might overestimate resistance, particularly in isolates with MICs close to the resistance breakpoint), whereas MIC values from Etest V R appeared to be lower than those of the BMD reference method (Table 1) . This is in agreement with Jorgensen and Crawford, 11 but contrasts with several previous reports, where Etest V R delivered mostly elevated MICs in comparison with the reference BMD. 12, 13 Slight MIC variations might be caused by differences in the calcium concentrations of the test systems (the actual calcium amount of the media was not checked in this study), which has previously been described for different media or medium lots. 8, 14 For the gradient strips used in this study, the manufacturers comment that calcium incorporation levels may vary and it has recently been shown that even between strips from the same manufacturer, lot-related MIC discrepancies have occurred. 15 Glycopeptide cross-'non-susceptibility'
Among the 86 daptomycin-non-susceptible S. aureus isolates investigated in this study 28 (33%) revealed elevated vancomycin MICs (2-4 mg/L; Table S1 ). While all isolates with a vancomycin MIC of 4 mg/L (n " 4) were MRSA and exhibited daptomycin MICs of Grey shaded area indicates a maximum of one 2-fold dilution difference between MICs obtained with different methods.
Comparing methods for S. aureus daptomycin susceptibility testing JAC 4-8 mg/L, among the remaining 24 isolates 15 (17%; 15 of 86) were phenotypic MSSA affiliated to various clonal lineages. Cross-resistance between glycopeptides and daptomycin has been described before; its development is complex and associated with genetic events in several evolutionary pathways. 5 However, cross-resistance has been reported in MRSA rather than in MSSA so far and resistance development could be linked to previous antibiotic treatment. 5 In this respect our study is limited, as we have no treatment information for the strains investigated. Nonetheless, the proportion of MSSA exhibiting elevated glycopeptide MICs is alarming.
Overall, our results indicate that routine laboratories are at only limited risk of overlooking resistance development, as long as commercially available test systems are used according to the manufacturer's recommendations. However, they should be aware of the emergence of daptomycin resistance in MRSA and MSSA alike, which can be associated with elevated MICs of glycopeptides.
